Financials Positive

2026-05-29 16:15

Consolidated Revenue ₹35.43 Cr vs ₹22.50 Cr (▲57.52% YoY), EBITDA ₹18.64 Cr vs ₹12.86 Cr (▲44.93% YoY), PAT ₹9.80 Cr vs ₹8.04 Cr (▲22.02% YoY). EBITDA Margin 52.61% vs 57.18% (▼457bps). The Board also recommended a final dividend of ₹5.00 per equity share (50%) for the financial year ended March 31, 2026.

Financials Positive

2026-05-29 15:59

Consolidated Revenue ₹35.43 Cr vs ₹22.50 Cr (▲57.5% YoY), EBITDA ₹8.49 Cr vs ₹7.92 Cr (▲7.2% YoY), PAT ₹9.80 Cr vs ₹8.04 Cr (▲21.9% YoY). EBITDA Margin 23.97% vs 35.21% (▼1124 bps). The Board recommended a final dividend of 50% (Rs. 5.00 per equity share of face value Rs. 10/-) for FY 2025-26. M/s Ali Jain & Sharma were appointed as Internal Auditors for FY 2026-27.

Financials Positive

2026-05-29 15:45

The Board of Directors of 3B BlackBio Dx Ltd. approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. Consolidated Revenue for Q4 FY26 was ₹35.43 Cr vs ₹22.50 Cr (▲57.52% YoY), EBITDA was ₹18.64 Cr vs ₹12.86 Cr (▲44.93% YoY), and PAT was ₹9.80 Cr vs ₹8.04 Cr (▲22.02% YoY). EBITDA Margin was 52.61% vs 57.18% (▼457bps). The Board also recommended a final dividend of Rs. 5.00 per equity share (50%) for FY26.

Business Update Neutral

2026-05-26 16:55

3B BlackBio Dx Ltd. announced an earnings conference call for investors and analysts on Monday, June 1, 2026, at 4:00 PM (IST). The call will discuss the company's operational and financial performance for the quarter and financial year ended March 31, 2026.

Governance Negative

2026-05-22 17:38

CRITICAL RED FLAG DETECTED

3B BlackBio Dx Ltd. submitted its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report by Practicing Company Secretary, P.K. Rai & Associates, confirms the company's general compliance with SEBI Listing Obligations and Disclosure Requirements. However, the report details past non-compliances related to the appointment of directors in FY24 (Smt. Mithla Dubey and Mr. Shabbar Hussain) without proper prior approval, which led to regulatory penalties totaling ₹4,15,360 (₹2,14,760 + ₹2,00,600). The company's waiver requests for these penalties were rejected, and the penalties were duly paid.

Governance Neutral

2026-05-20 15:29

3B BlackBio Dx Ltd. announced that a Board Meeting will be held on Friday, May 29, 2026, at 3:00 P.M. to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter/financial year ended March 31, 2026. The board will also discuss the recommendation of a dividend, if any, for the same financial year. The trading window for the Company's shares will remain closed from April 1, 2026, until 48 hours after the results are announced.

Business Update Positive

2026-04-21 17:19

3B BlackBio Dx Limited's equity shares have been admitted for trading on the National Stock Exchange of India Limited under the "Permitted to Trade" category, effective April 20, 2026, as per NSE Circular Ref. No. 73797 dated April 17, 2026.

Routine Neutral

2026-04-15 17:10

3B BlackBio Dx Ltd. submitted a declaration confirming that it does not fall under the category of 'Large Corporate' as per the SEBI circular dated October 19, 2023, and thus the related disclosure requirements are not applicable to the company.

Routine Neutral

2026-04-15 17:05

3B BlackBio Dx Ltd. confirmed the non-applicability of disclosure requirements for Large Corporates as per the SEBI circular dated October 19, 2023. This indicates the company does not meet the criteria to be classified as a Large Corporate for compliance purposes.

Routine Neutral

2026-04-14 17:11

3B BlackBio Dx Ltd. (formerly Kilpest India Limited) confirmed on April 14, 2026, that it does not fall under the category of 'Large Corporate' for disclosure requirements as per the SEBI circular dated October 19, 2023.

Ownership Positive

2026-04-04 16:20

Promoter Nikhil Kuber Dubey, on behalf of the Promoter & Promoter Group of 3B BlackBio Dx Ltd, has declared that no shares were encumbered or pledged during the financial year ended March 31, 2026, as per SEBI SAST Regulation 31(4).

Ownership Neutral

2026-03-26 17:37

3B BlackBio Dx Ltd. announced the closure of its trading window from April 1, 2026, until 48 hours after the Audited Financial Results for the financial year ending March 31, 2026, are submitted to the Stock Exchange, as per SEBI PIT Regulations 2015.

Business Update Neutral

2026-03-17 17:13

3B BlackBio Dx Ltd. held a one-to-one investor meeting with Fair Value Capital (India Insight Value Fund) on March 17, 2026. The company reiterated information from its Q3-FY26 Investor Presentation, which covered financial results for the quarter and nine months ended 31-12-2025. No unpublished price sensitive information was shared.

Business Update Neutral

2026-03-12 14:26

3B BlackBio Dx Ltd. announced an Analyst/Investor Meeting on March 17, 2026, at 4:00 PM with Fair Value Capital (India Insight Value Fund) via virtual meeting. The company will use its Q3-FY26 Investor Presentation, assuring no unpublished price-sensitive information will be shared.

Business Update Positive

2026-02-24 15:43

Transcript of the Q3 FY26 earnings call held on Feb 21, 2026, discussing results for the period ended Dec 31, 2025. The company highlighted significant growth, with nine-month revenue at INR 99.06 Cr (including Coris). They expect 10-15% full-year revenue and EBITDA growth, and 15-20% export growth, while managing increasing competition and extended credit cycles.

Business Update Neutral

2026-02-21 14:59

3B BlackBio Dx Ltd. announced on February 21, 2026, the upload of the audio recording of its Analysts/Investors Call concerning the unaudited financial results for the third quarter and nine months ended December 31, 2025, on its website.

Business Update Positive

2026-02-19 13:53

CEO updated shareholders on successful participation at MEDLAB Dubai, securing M&A leads, achieving significant brand recognition, and generating new business opportunities for Coris. The company received widespread praise for its quality and support.

Financials Neutral

2026-02-18 13:05

The company has re-scheduled its Earning Concall for investors and analysts from February 18, 2026, to February 21, 2026, at 12:00 PM IST, to discuss the Q3 FY26 operational and financial results for the quarter and nine months ended December 31, 2025.

Financials Negative

2026-02-07 14:45

Consolidated Revenue ₹19.83Cr vs ₹19.62Cr (▲1.1% YoY), EBITDA ₹2.40Cr vs ₹15.22Cr (▼84.2% YoY), PAT ₹2.24Cr vs ₹15.04Cr (▼85.1% YoY). EBITDA Margin 12.1% vs 77.6% (▼6550bps).

Financials Neutral

2026-02-06 17:41

3B BlackBio Dx Ltd. announced an earnings conference call for investors and analysts on February 18, 2026, at 4:00 PM (IST) to discuss the financial results for the quarter and nine months ended December 31, 2025.

Financials Positive

2026-02-06 16:30

Consolidated Revenue from Operations ₹50.35Cr vs ₹25.39Cr (▲98.3% YoY), PBT ₹26.84Cr vs ₹17.80Cr (▲50.8% YoY), PAT ₹22.44Cr vs ₹13.50Cr (▲66.3% YoY). The reported figures for Q3 2025-26 include a one-time CORIS sales and profit impact.

Financials Positive

2026-02-06 16:18

Consolidated Revenue ₹50.35Cr vs ₹25.39Cr (▲98.28% YoY), EBITDA ₹21.72Cr vs ₹15.07Cr (▲44.07% YoY), PAT ₹22.44Cr vs ₹13.50Cr (▲66.30% YoY). EBITDA Margin 43.13% vs 59.36% (▼1623bps).

Financials Positive

2026-02-06 16:11

Consolidated Revenue ₹50.35Cr vs ₹25.39Cr (▲98.3% YoY), EBITDA ₹21.72Cr vs ₹15.07Cr (▲44.1% YoY), PAT ₹22.44Cr vs ₹13.50Cr (▲66.3% YoY). EBITDA Margin 43.1% vs 59.4% (▼1630bps). The current quarter's results include CORIS sales of ₹24.01Cr and profit of ₹7.00Cr.

Governance Neutral

2026-01-30 15:35

Board Meeting of 3B BlackBio Dx Ltd. to be held on February 6, 2026, to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Trading window closed from January 1, 2026.

532067

3B BLACKBIO DX LTD

Filing History

Unlock Full History